Participated · Series A · Nov 2024

Medeloop is an AI-driven medical research platform based in Menlo Park, California. Led by CEO Rene Caissie, it automates the entire research cycle—from grant discovery to data analysis—by transforming medical data into a graph database to deliver deep insights and fast results. Its suite includes a grant platform for identifying and applying for funding, a dual-component studies platform (mobile app for participants and web app for researchers), a no-code analytics platform, and a manuscript publication platform. These integrated tools are designed to let researchers manage every aspect of a study from inception to publication. Medeloop partners with healthcare institutions worldwide. The company intends to use the new funds to expand operations and accelerate development efforts. Medeloop offers an AI-driven platform that integrates, harmonizes, and analyzes health data using advanced AI tools to support clinical research. The product streamlines researcher discovery and simplifies grant applications, data collection and harmonization, biomarker and trend identification, and manuscript submissions. Medeloop says these insights have the potential to expedite the clinical research process. The company plans to use the funds to launch an end-to-end solution for early-stage clinical research. Leadership includes CEO Dr. Rene Caissie, CTO Raghav Samavedem, CSO Dr. Josh Walonoski, and COO Andy Yakulis. Medeloop is based in Palo Alto, CA.

Participated · Equity · Sep 2024

Novatus offers En:ACT, a SaaS platform that helps financial institutions manage data for risk and regulatory reporting. The company was founded by Andrew Hedley and Matthew Ransom, who came from risk roles at Vanguard/Prudential and Deloitte respectively. Novatus pairs its automation with an advisory service of humans who tailor the platform for specific use cases. It serves some 30 major clients, including MUFG, NatWest Group, Revolut, Wellington, Allspring and Artemis. The company has offices in London and Sydney and plans to use new funding to invest in its technology and expand into North America. Novatus recently completed a $40M fundraise at a post-money valuation in the region of $150M.

Participated · Series A · Sep 2024

Novatus offers En:ACT, a SaaS platform that helps banks, investment firms and other financial services providers manage complex data to meet reporting and compliance requirements. The product couples automation with human advisers who tailor the platform to specific use cases. Founders Andrew Hedley and Matthew Ranson started the company after seeing industry-wide problems in data transparency and risk at institutions like Vanguard, Prudential and Deloitte. The company serves roughly 30 major clients, including MUFG, NatWest Group, Revolut, Wellington, Allspring and Artemis. Novatus has offices in London and Sydney and plans to use new funding to invest in technology and expand into North America. Financially, the company recently closed a $40M Series A that sources say implies a post-money valuation in the region of $150M.

Led · Equity · Jul 2024

Traverse Associates supplies automation services that streamline back-office tasks for travel and leisure businesses. Established in 2007, the company is based in Preston Brook near Runcorn and maintains offices in Hampshire. Its core product set includes a newly developed proprietary intelligent automation technology called Cognitive Flow. The business has been scaling since Maven first backed it in 2023 and has more than doubled its annual licence fees since that investment. The latest funding will be used to accelerate development and growth of Cognitive Flow and support the company’s next phase of expansion. Advisors on the deal were Browne Jacobson (for Maven) and Ward Hadaway (for Traverse).

Participated · Seed · May 2024

Founded in 2021 as a University of Glasgow spin-out, Nami Surgical is engineering high-performance, miniaturised ultrasonic scalpels that can be embedded into articulated, wristed robotic surgical instruments. The platform aims to fill a technology gap for major medical robotic companies, giving surgeons ultrasonic cutting and coagulation capability inside compact robotic tools. With the global robotic-assisted surgery market expected to exceed $25 billion by 2030, Nami is positioning its technology for broad commercial adoption. The company is now transitioning from advanced development to commercialisation and has strengthened its leadership by appointing veteran MedTech executive Nikki Palfrey as CEO while co-founder Nico Fenu becomes COO. Recent board additions, including Eos Advisory’s Investor Director David O’Reilly, bolster governance and strategic expertise. To date the firm has attracted backing from deep-tech investor Eos Advisory, Maven Capital Partners, and Scottish Enterprise, underscoring continued investor confidence as the product nears market entry.